Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$96 Mln
Revenue (TTM)
$-4 Mln
Net Profit (TTM)
$0 Mln
ROE
-4.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
--
EV/EBITDA
0.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-9.5
Face value
--
Shares outstanding
22,077,467
CFO
$-614.44 Mln
EBITDA
$-774.85 Mln
Net Profit
$-914.61 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Adverum Biotechnologies (ADVM)
| -6.6 | 0.9 | 23.2 | -26.2 | -11.1 | -49.7 | -26.4 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Adverum Biotechnologies (ADVM)
| -37.7 | 29.9 | -67.0 | -83.8 | -5.9 | 265.7 | -9.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Adverum Biotechnologies (ADVM)
|
4.4 | 96.3 | -3.6 | -204.4 | 4,048.0 | -- | -- | 0.9 |
| 54.7 | 4,499.0 | 0.0 | -292.8 | -7,205,162.5 | -28.7 | -- | 4.7 | |
| 1.6 | 116.1 | 0.4 | -98.2 | -10,576.5 | -834.6 | -- | 27.3 |
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used... for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Read more
President, CEO & Director
Dr. Laurent Fischer
President, CEO & Director
Dr. Laurent Fischer
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Adverum Biotechnologies Inc (ADVM) is $4.36 (NASDAQ) as of 09-Dec-2025 09:30 EDT. Adverum Biotechnologies Inc (ADVM) has given a return of -11.07% in the last 3 years.
Since, TTM earnings of Adverum Biotechnologies Inc (ADVM) is negative, P/E ratio is not available.
The P/B ratio of Adverum Biotechnologies Inc (ADVM) is 0.93 times as on 09-Dec-2025, a 76 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.74
|
1.38
|
|
2023
|
-0.36
|
0.65
|
|
2022
|
-0.22
|
0.19
|
|
2021
|
-1.19
|
0.55
|
|
2020
|
-9.02
|
2.44
|
The 52-week high and low of Adverum Biotechnologies Inc (ADVM) are Rs 6.12 and Rs 1.78 as of 03-Apr-2026.
Adverum Biotechnologies Inc (ADVM) has a market capitalisation of $ 96 Mln as on 09-Dec-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Adverum Biotechnologies Inc (ADVM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.